Status and phase
Conditions
Treatments
About
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female, ≥18 and ≤55 years of age at the time of Screening
Has a caregiver or some other identified responsible person (e.g., family member, social worker, caseworker, or nurse) considered reliable by the Investigator in providing support to the subject to help ensure compliance with study treatment, study visits, and protocol procedures, and who is also able to provide input helpful for completing study rating scales
Diagnosis of schizophrenia made ≥1 year prior to Screening
Is being treated must be one of the antipsychotics listed below:
Aripiprazole
Aristada®
Asenapine
Brexpiprazole
Cariprazine
Lurasidone
Olanzapine
Paliperidone extended release (ER) (≤9 mg)
Paliperidone palmitate
Risperidone
Risperidone long-acting injection
Must be medically stable (including no recent hospitalization for exacerbation of psychiatric disorder) and has been medically stable for at least 12 weeks prior to Screening, in the opinion of the Investigator
Exclusion criteria
Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and condition do not meet all prespecified entry criteria).
Primary purpose
Allocation
Interventional model
Masking
454 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Sandra Filosi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal